Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 10/07/2025			5-day change	1st Jan Change
55.49 ^CNY	+0.89%		-1.03%	+25.83%

07-09	Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y	RE
07-08	Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina	CI

Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2024

Published on 22/10/2024 at 09:25

Gan & Lee Pharmaceuticals. reported earnings results for the nine months ended September 30, 2024. For the nine months, the company reported sales was CNY 2,245.01 million compared to CNY 1,905.67 million a year ago.

Revenue was CNY 2,245.01 million compared to CNY 1,905.67 million a year ago. Net income was CNY 507.27 million compared to CNY 266.48 million a year ago. Basic earnings per share from continuing operations was CNY 0.85 compared to CNY 0.47 a year ago.

Diluted earnings per share from continuing operations was CNY 0.85 compared to CNY 0.47 a year ago.

Latest news about Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y	07-09	RE
Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina	07-08	CI
Gan & Lee Pharmaceuticals Presents Multiple Results in Novel Diabetes Therapies At the American Diabetes Association's 85Th Scientific Sessions	06-21	CI
Gan & Lee Pharmaceuticals Completes First Patient Dosing in GZR102 Trial	05-19	MT
Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10%	04-25	MT
Gan & Lee Pharmaceuticals' Q1 Profit Surged 225%, Operating Income Jumps 76%; Shares Jump 10%	04-25	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-24	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial Diabetes Drug	04-23	MT
Gan & Lee Pharma's Insulin Glargine Injection Gets Registration Nod in Pakistan	04-02	MT
Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	04-01	CI
Gan & Lee Pharmaceuticals Doses First Subject for Phase II Clinical Trial of Bovanglutide Injection	03-11	MT
Gan & Lee Pharmaceuticals Announces First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide Injection for Overweight or Obesity	03-10	CI
Gan & Lee Pharma Doses First Subject for Insulin Drug's Phase III Trial; Shares Up 3%	02-18	MT
Gan & Lee Pharmaceuticals Registers Diabetes Treatment Drug	02-11	MT
Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	01-02	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from Shanghai Stock Exchange 180 Value Index	12-16	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from SSE 180 Index	12-16	CI
Gan & Lee Pharmaceuticals Gets US FDA Approval for Clinical Trials of Weight Control Drug	12-13	MT
Gan & Lee Pharmaceuticals Announces Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks	11-12	CI
Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults	11-11	CI
Gan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial	24/10/24	MT
Gan & Lee Pharmaceuticals Q3 Profit Up 57%; Shares Climb 3%	23/10/24	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2024	22/10/24	CI
Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	09/10/24	CI
Gan & Lee Pharmaceuticals. announces an Equity Buyback for CNY 300 million worth of its shares.	05/09/24	CI

Chart Gan & Lee Pharmaceuticals.

Duration

Period

603087: Dynamic Chart

Company Profile

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Employees

5,245

Sector

Pharmaceuticals

Calendar

08-07 - Q2 2025 Earnings Release

More about the company